Dr. Georges Adunlin co-authored a study that has recently been published in Breast Cancer Research and Treatment.
September 23, 2016
As more treatment options become available for HER2-positive metastatic breast cancer (mBC), some questions remain about the optimal sequencing of therapies in this patient population. We identified this area as high priority for original economic analysis. Therefore, a Markov model analysis using data from multiple sources was developed to assess the cost-effectiveness of four different HER2 targeted treatment sequences in patients with HER2-positive mBC treated in the U.S. The Markov model was developed in close collaboration with a team of clinicians. Overall, results of the economic analysis showed that the least clinically effective sequence (1.27 QALYs), but most cost-effective at a total cost of $149,250.19, was trastuzumab/docetaxel as first-line therapy, trastuzumab emtansine (T-DM1) as second-line therapy, and trastuzumab/lapatinib as third-line therapy. The study also provides a framework for establishing value-based pricing for all new oncology drugs entering the U.S marketplace.
Georges Adunlin, the second author considers this study to be innovative because no previous study has characterized the treatment sequences commonly administered specifically to patients with HER2-positive mBC and evaluated the cost-effectiveness of treatment sequences using real-world data.